ACHV - Achieve Life Sciences, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ACHV

ACHIEVE LIFE SCIENCES, INC.

NASDAQ

$8.10

▼ DOWN 0.98% (-0.08)

KEY STATISTICS

Market Cap$831.54 M

52w High$8.61

52w Low$2.62

Dividend Yield—

Frequency—

P/E-5.23

Volume988.89K

Shares Out.102.66M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Andrew D. Goldberg

COMPENSATION 2026

Salary$615,000

Stock Awards$522,900

Incentive Plan Pay$230,625

All Other Comp.$0

Total$1,368,525

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 12, 1995

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

PRICE TARGET

Target High$18.00

Target Low$12.00

Target Median$13.00

Target Consensus$14.00

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.$10.65M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2020-07-31	Reverse	1:20
2018-05-24	Reverse	1:10
2017-08-03	Reverse	1:11
2008-08-21	Reverse	1:18

PRICE

$8.10 ▼ DOWN 0.98% (−$0.08)

OVERLAYS

About Achieve Life Sciences, Inc.

https://www.achievelifesciences.com ↗

Achieve Life Sciences, a Vancouver-based clinical-stage pharma company, develops cytisinicline for smoking cessation and nicotine addiction in North America and the UK, with licensing agreements with Sopharma AD and the University of Bristol.

INDUSTRY

Biotechnology

A PRODUCT ACHIEVE LIFE SCIENCES, INC. IS KNOWN FOR

Cytisinicline

Cytisinicline, a plant-based alkaloid developed by Achieve Life Sciences, is a leading investigational treatment for smoking cessation and nicotine dependence, with an NDA under review by the FDA.